Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Providence Hospital - Southfield
mi
from
Southfield, MI
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Providence Hospital - Southfield
mi
from
Southfield, MI
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Biloxi
mi
from
Biloxi, MS
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Biloxi
mi
from
Biloxi, MS
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
University of Mississippi Medical Center
mi
from
Jackson, MS
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Jackson
mi
from
Jackson, MS
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Jackson
mi
from
Jackson, MS
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Keesler Medical Center - Keesler AFB
mi
from
Keesler AFB, MS
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Keesler Medical Center - Keesler AFB
mi
from
Keesler AFB, MS
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Kansas City
mi
from
Kansas City, MO
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Kansas City
mi
from
Kansas City, MO
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
St. Louis University Health Sciences Center
mi
from
Saint Louis, MO
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
St. Louis University Health Sciences Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - St. Louis-Cape Girardeau
mi
from
Saint Louis, MO
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - St. Louis-Cape Girardeau
mi
from
Saint Louis, MO
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Albuquerque
mi
from
Albuquerque, NM
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Albuquerque
mi
from
Albuquerque, NM
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
MBCCOP - University of New Mexico HSC
mi
from
Albuquerque, NM
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
MBCCOP - University of New Mexico HSC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Barrett Cancer Center, The University Hospital
mi
from
Cincinnati, OH
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Barrett Cancer Center, The University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Cincinnati
mi
from
Cincinnati, OH
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Columbus
mi
from
Columbus, OH
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Columbus
mi
from
Columbus, OH
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Dayton
mi
from
Kettering, OH
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Dayton
mi
from
Kettering, OH
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Oklahoma City
mi
from
Oklahoma City, OK
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Oklahoma City
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Oregon Cancer Center at Oregon Health Sciences University
mi
from
Portland, OR
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Oregon Cancer Center at Oregon Health Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Portland
mi
from
Portland, OR
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Portland
mi
from
Portland, OR
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Columbia River Program
mi
from
Portland, OR
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Columbia River Program
mi
from
Portland, OR
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Greenville
mi
from
Greenville, SC
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
University of Texas Medical Branch
mi
from
Galveston, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Texas Tech Univ. Hlth Sci. Ctr.
mi
from
Lubbock, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Texas Tech Univ. Hlth Sci. Ctr.
mi
from
Lubbock, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Scott and White Hospital
mi
from
Temple, TX
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Scott and White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Swedish Cancer Institute
mi
from
Seattle, WA
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated:  10/23/2015
CCOP - Northwest
mi
from
Tacoma, WA
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623
Status: Enrolling
Updated: 10/23/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Status: Enrolling
Updated:  10/26/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Status: Enrolling
Updated: 10/26/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated:  10/26/2015
Jackson Health System
mi
from
Miami, FL
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated: 10/26/2015
Jackson Health System
mi
from
Miami, FL
Click here to add this to my saved trials
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated:  10/26/2015
University of Miami
mi
from
Miami, FL
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated: 10/26/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/27/2015
UCLA
mi
from
Los Angeles, CA
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/27/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CP-724,714 in Treating Patients With Metastatic Breast Cancer
A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
CP-724,714 in Treating Patients With Metastatic Breast Cancer
A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Status: Enrolling
Updated:  10/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Status: Enrolling
Updated: 10/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan-Kettering Cancer Center at Mercy
mi
from
Rockville Centre, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan-Kettering Cancer Center at Mercy
mi
from
Rockville Centre, NY
Click here to add this to my saved trials